Document is current
Any future updates will be listed below
-
Authors
Su, Guobin
Xiao, Ruowei
Ji, Dongze
He, Kaiyu
Hallert, Anna
Savarese, Gianluigi
Lund, Lars H.
Xu, Yang
Carrero, Juan Jesus
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82004205, 82174308)
the Spring Sunshine Program of Scientific Research Cooperation, Ministry of Education of China (HZKY20220109)
National Administration of Traditional Chinese medicine, P.R. China (2023ZYLCYJ02-18)
Research Fund for Bajian Talents of Guangdong Provincial Hospital of Chinese Medicine (BJ2022KY11)
the Science and Technology Research Fund from Guangdong provincial hospital of Chinese medicine, China (YN2024MS012, YN2020QN18, YN2020QN24)
the Karolinska Institutet’s research grant (2020-01616, 2022-02044)
Sanming Project of Medicine in Shenzen Municipality (SZZYSM202206014)
National Institutes of Health (R01DK115534, R01DK115534)
the Swedish Research Council (2023-01807)
the Swedish Heart and Lung Foundation (20230371)
Region Stockholm (ALF Medicine, FoUI-986028)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 7 January 2025
Accepted: 25 July 2025
First Online: 12 August 2025
Declarations
:
: The Regional Ethics Review Board in Stockholm approved the study; informed participant consent was not deemed necessary since all data were de-identified at the Swedish Board of Health and Welfare (reference 2017/793-31).
: Not applicable.
: G.S2. reports grants and personal fees from CSL Vifor, Boehringer Ingelheim, AstraZeneca, Servier, Novartis, Cytokinetics, Pharmacosmos, Medtronic, Bayer, and personal fees from Roche, Abbott, Edwards Lifescience, TEVA, Menarini, INTAS, GETZ, and grants from Boston Scientific, Merck, all outside the submitted work. Unrelated to the present manuscript: Grants, consulting, speakers honoraria to authors institution: Alleviant, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards, Owkin, Pharmacosmos. Other authors have no competing interest to declare.
